SCHEMBL3449762

SCHEMBL3449762

COc1cc(F)cc(Nc2ncc(-c3ccc(C(=O)O)o3)c(-n3ccc(C(F)(F)F)n3)n2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 5/20 0.39
CNR2 P34972 3/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
MAPK3 P27361 1/20 0.36
JAK2 O60674 1/20 0.35
CYP3A4 P08684 1/20 0.35
JAK1 P23458 1/20 0.35
JAK3 P52333 1/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
SYK P43405 2/20 0.34
BTK Q06187 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449137 0.84 CSNK2A1 (0.43) IDH1CNR2HDAC3HDAC1HDAC2
SCHEMBL13312523 0.84 SYK (0.41) IDH1HDAC3HDAC1HDAC2HDAC6
SCHEMBL3451542 0.84 SYK (0.44) IDH1CNR2SYKBTKEGFR
SCHEMBL3448415 0.84 SYK (0.39) IDH1CNR2HDAC3HDAC1HDAC2
SCHEMBL3451069 0.81 SYK (0.38) IDH1CNR2HDAC3HDAC1HDAC2
SCHEMBL3463734 0.81 IDH1 (0.38) IDH1CNR2HDAC3HDAC1HDAC2
SCHEMBL3448604 0.80 IDH1 (0.46) IDH1HDAC3HDAC1HDAC2HDAC6
SCHEMBL13312476 0.79 THRB (0.37) IDH1CNR2MAPK3SYKBTK
SCHEMBL3376553 0.78 PDGFRB (0.40) HDAC3HDAC1HDAC2HDAC6MAPK3
SCHEMBL3375491 0.78 SYK (0.41) CNR2HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD IDH1 718/4885CNR2 517/4885HDAC3 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.